Purpose: Activation of the innate immune system plays a significant role in pathologies of the central nervous system (CNS). In order to follow disease progression and evaluate effectiveness of potential treatments involved in neuroinflammation, it is important to track neuroinflammatory markers in vivo longitudinally. The translocator protein (TSPO) is used as a target to image neuroinflammation as its expression is upregulated in reactive glial cells during CNS pathologies. However, it remains unclear in which microglial phenotypes TSPO levels are upregulated, as microglia can display a plethora of activation states that can be protective or detrimental to the CNS. Procedures: We assessed the levels of TSPO transcripts in cultured microglia that were polarized into pro-and anti-inflammatory states in vitro and in the brain of mice in which an antiinflammatory environment was induced in vivo. In addition, we used a mouse model of peroxisomal multifunctional protein-2 (MFP2) deficiency that exhibits widespread neuroinflammation despite no neuronal loss and monitored TSPO expression by immunohistochemistry and by imaging using the TSPO radiotracer [
Introduction
The innate immune system is implicated in all neurodegenerative disorders. The key players in neuroinflammatory processes are microglia and astrocytes. They become reactive, typically change their morphology, and acquire modified functions [1, 2] . Neuroinflammation often precedes neuronal loss in neurodegenerative disorders such as in Alzheimer's disease (AD) and Parkinson's disease (PD) [3, 4] . Therefore, it is important to detect neuroinflammatory processes in presymptomatic stages as they mark early stages of neuropathology. The most studied biomarker for imaging of neuroinflammation is the 18-kDa translocator protein (TSPO), previously known as the peripheral benzodiazepine receptor (PBR), which is primarily expressed on the outer mitochondrial membrane of microglia and macrophages [5, 6] . The TSPO is important for brain development and homeostasis during adulthood as it plays a crucial role in neurosteroidogenesis [7, 8] . TSPO expression in the CNS is low under healthy circumstances, but increases mainly in microglia in response to neuronal insults such as in the neurodegenerative diseases PD, AD, amyotrophic lateral sclerosis (ALS), and Huntington disease (HD) [9, 10] . Reactive astrocytes can also induce TSPO expression in addition to reactive microglia [11] .
It is still a matter of debate whether neuroinflammation accelerates or delays disease progression in neurological disorders. Reactive microglia play Janus-like roles in neurological disorders. During pathology, activated microglia can promote not only tissue injury (denoted as an M1 phenotype) but also tissue repair and remodeling (denoted as an M2 phenotype), dependent on the type of disease and stage of disease progression [12, 13] . Therefore, it is important to precisely characterize neuroinflammation in vivo in order to apply anti-inflammatory therapies only during harmful functioning of the innate immune system. Although TSPO is generally accepted as an appropriate marker of neuroinflammation, the functional link between TSPO and neuroinflammation remains unknown. It is unclear whether increased TSPO expression is associated with pro-inflammatory and neurotoxic responses (classically activated or M1 microglia) or with anti-inflammatory responses and tissue repair (alternatively activated or M2 microglia), or both. Whereas the association of TSPO with specific inflammatory states is poorly documented [14] , this information is necessary to correctly interpret increased TSPO levels in vivo in clinical conditions and to adapt inflammatory therapies according to the need and disease stage of patients.
In this study, we aimed to better define in which neuroinflammatory conditions TSPO is induced. First, microglia were isolated from wild-type brain and TSPO transcript expression was analyzed after polarization of the microglia into a pro-or anti-inflammatory state. This was complemented by an in vivo study in which an anti-inflammatory brain environment was created by intracerebroventricular (i.c.v.) injection of IL-4. In addition, we used a mouse model of peroxisomal β-oxidation deficiency, more specifically multifunctional protein-2 (MFP2)-deficient mice, which develop robust and chronic neuroinflammation before the age of 8 weeks that progressively increases until death around the age of 17 weeks [15] [16] [17] . The mechanisms underlying this widespread gliosis were not elucidated yet, but likely, an interplay of cell-autonomous deregulation due to loss of MFP2 in microglia and microglial reactivity to neuronal dysfunction are involved [15, 16] . Different from most other neuropathological disease models in which neuroinflammation develops, Mfp2 −/− mice do not show neuronal loss [17] . We previously characterized the proliferative Mfp2 −/− microglia extensively and found that they are of local origin, are immunologically activated, but display a mixed pro-(M1) and anti-(M2) inflammatory phenotype [17] . Of note, they do not express detrimental neuroinflammatory markers such as iNOS. We investigated whether TSPO is induced in this inflamed but non-neurodegenerative brain environment by immunohistological and gene expression studies and by in vitro, ex vivo, and in vivo TSPO imaging using the TSPOspecific radiotracer [ 
Materials and Methods

Mouse Breeding
Mfp2
−/− mice were generated as previously described [18] .
−/− mice were bred on a Swiss/Webster background in a specific pathogen-free animal housing facility of the KU Leuven, had ad libitum access to water and standard rodent food, and were kept on a 12-h light and dark cycle. All animal experiments were performed in accordance with the BGuidelines for Care and Use of Experimental Animals^and fully approved by the Research Ethical committee of the KU Leuven (no. 190/2012). Both wild-type and heterozygous mice were used as controls as no differences were detected in our previous investigations [15] [16] [17] . Details of the immunohistochemistry, quantitative real-time (qRT)-PCR, primary microglial cell culture, and i.c.v. injections are provided in the Supplementary material.
In vitro Autoradiography
The mice (n = 3/group) were sacrificed at an age of 19 weeks, and the brain was removed, rinsed with saline to remove blood, rapidly frozen in 2-methylbutane (−40°C), and stored at −20°C for 24 h. Brain sagittal sections were obtained using a cryotome (Shandon cryotome FSE; Thermo Fisher, Waltham, USA), mounted on adhesive microscope slides (Superfrost Plus; Thermo Fisher), and stored at −20°C until autoradiography was performed. Brain slices were dried and pre-incubated in tris-HCl 50 mM buffer (pH 7.4) for 10 min at room temperature. Before incubation with [ 18 F]DPA-714, the brain sections were dried. The brain sections were incubated with 300 kBq (in 500 μl tris-HCl 50 mM buffer) of tracer for 10 min or tracer in the presence of 20 μM of the blocking agent PK11195 (Sigma Aldrich, St. Louis, MO, USA) for 10 min. The brain sections were washed twice for 10 min in tris-HCl 50 mM (pH 7.4) and 0.3 % BSA buffer at 4°C. After a quick dip in water at 4°C, the slides were dried. Autoradiograms were obtained by exposing the slides for 5 min to a high-performance phosphor storage screen (super-resolution screen; Perkin Elmer, Waltham, USA). The screens were read using a Cyclone Plus system (Perkin Elmer) and analyzed using Optiquant software (Perkin Elmer). The radioactivity concentration in the autoradiograms is expressed in digital light units (DLU) per square millimeter (mm 2 ), corrected for background. All statistical studies were performed with the unpaired two-tailed Student t test. Calculations were carried out using GraphPad Prism v5.0 (San Diego, CA).
Ex vivo Autoradiography
The mice (16 weeks old, n = 6/group) were injected with the tracer (22 ± 0.6 MBq, mean ± SD) via a tail vein under anesthesia (2.5 % isoflurane in O 2 at 1 l/min flow rate) and were kept under anesthesia until they were sacrificed by decapitation at 30 min (n = 3/group) and 60 min (n = 3/group) post tracer injection. The brain was removed and rapidly frozen in 2-methylbutane (between −30 and −40°C). Twentymicrometer sagittal sections from the brain were obtained using a cryotome (Shandon cryotome FSE, Thermo Fisher, Waltham, USA), mounted on adhesive microscope slides (Superfrost Plus, Thermo Fisher Scientific), and exposed to a phosphor storage screen film (super-resolution screen; Perkin Elmer, Downers Grove, IL, USA) for 35 min. The screens were read using a Cyclone® Plus system (Perkin Elmer) and analyzed using Optiquant software (Perkin Elmer). The results were expressed as digital light units per square millimeter normalized for body weight of the animal and injected dose [(DLU/mm 2 ) × (body weight/injected dose)].
MicroPET
Imaging experiments were performed on a Focus 220 micropositron emission tomography (microPET) scanner (Concorde Microsystems, Knoxville, TN, USA). Six Mfp2 −/− (26.5 ± 2.7 g, mean ± SD) and six control mice (39.8 ± 5.9 g) were scanned at end stage of disease, between 14 and 19 weeks of age. The mice were injected with 22 ± 0.6 MBq (mean ± SD) of [ 18 F]DPA-714 via a tail vein (volume injected G0.3 ml). During all PET sessions, the animals were kept under gas anesthesia (2.5 % isoflurane in O 2 at a flow rate of 1 l/min). List-mode 90-min microPET scans were acquired. Acquisition data were then Fourier rebinned in 24 time frames (4 × 15 s (s), 4 × 60 s, 5 × 180 s, 8 × 300 s, 3 × 600 s) and reconstructed using maximum a posteriori iterative reconstruction. The images were spatially aligned to a rat brain 2-deoxy-2-[ 18 F]fluoro-Dglucose template in Paxinos coordinates [19] using an affine transformation, allowing the use of predefined volumes of interest map. Time-activity curves (TACs) were generated for total brain for each individual scan using PMOD software (version 3.2; PMOD technologies, Zurich, Switzerland).
Results
Induced TSPO Expression Is Restricted to Classically (M1) Activated Microglia
It is known that activated microglia exert dual functions, either pro-inflammatory (M1) functions that are rather harmful, or anti-inflammatory (M2) functions that are neuroprotective and regenerative [20] . While this M1-M2 distinction is an oversimplification and represents the extreme states, this subdivision is a nice strategy to associate certain disease phenomena with a specific activation state of microglia. Although TSPO is a well-known marker for general neuroinflammation, it is still unknown whether TSPO expression is induced during both pro-and antiinflammatory activation states of microglia or during a specific activation state only. In this study, we aimed to associate induced TSPO expression with either a proinflammatory (M1) or anti-inflammatory (M2) activation state of microglia. First, cultured primary microglia isolated from newborn wild-type mice were polarized into a proinflammatory phenotype by using either LPS or the combination of interleukin (IL)-1β and interferon gamma (IFNγ). Alternatively, they were brought into an antiinflammatory state by treating with IL-4 [21] [22] [23] . We verified that LPS and IL-1β/IFNγ polarize the microglia towards an M1 state by showing increased transcript expression of the pro-inflammatory markers Tnfa (Fig. 1a and Suppl. Fig. 2a ) and iNOS (Fig. 1a and Suppl. Fig. 2b ) compared to vehicle-treated (M0) microglia whereas the M2 marker arginase-1 (Arg1) remained barely detectable (Fig.  1c and Suppl. Fig. 2c ). Successful polarization to the M2 state with IL-4 was shown by strongly increased arginase-1 (Arg1) expression (Fig. 1c) and levels of iNOS and Tnfa that were unaltered compared to the M0 condition [21] . We found that Tspo transcript expression was induced in both groups of M1-activated microglia but did not change in M2-activated microglia (Fig. 1d and Suppl. Fig. 2d) . Subsequently, we questioned whether the selective induction of TSPO in pro-inflammatory microglia in vitro also occurred in neuroinflammatory conditions in vivo. We and others previously showed that TSPO expression is increased in models in which pro-inflammatory microglia predominate [24] [25] [26] . To induce an anti-inflammatory brain environment, we injected IL-4 in the third ventricle as previously reported [27, 28] . The expression of Tspo as well as of pro-and antiinflammatory markers was assessed 20 h later in the frontal cortex [27, 28] . As expected, the overall profile of the inflammatory markers coincided rather with an antiinflammatory than with a pro-inflammatory state (Fig. 2a-Fig. 1 Tspo transcript levels are increased in microglia during pro-inflammatory but not anti-inflammatory signaling. Analysis of transcripts levels by qRT-PCR to validate the pro-inflammatory M1 condition after LPS treatment and the anti-inflammatory M2 state after IL-4 treatment. The typical pro-inflammatory genes aTnfa and biNOS were only upregulated after LPS treatment and the anti-inflammatory gene cArg1 was only upregulated in IL-4-treated (M2) microglia. dTspo transcript levels are only significantly increased in M1-activated microglia but not in M2-activated microglia. Data are presented as mean ± SEM (n = 3/ group). *P G 0.05; ***P G 0.001. Fig. 2 Tspo transcript levels remain unchanged after IL-4 i.c.v. injections. With the exception of biNOS, the expression of typical pro-inflammatory markers aTnfa, cIl1b, and dIl6 was not altered in the frontal cortex after IL-4 injections in the third ventricle. e-g Transcripts levels of anti-inflammatory markers such as eArg1 and fFizz1 were markedly increased. g The Ym1 M2 marker was not significantly altered. h Transcript levels of Tspo remain unchanged after IL-4 injections in the third ventricle. Data are presented as mean ± SEM (n = 5/group). **P G 0.01; ***P G 0.001. g). In this particular condition, in which neuroinflammation was clearly established, the expression of Tspo transcripts was unaltered (Fig. 2h) . Together, these data demonstrate that Tspo expression is not induced in all inflammatory brain environments but rather marks a pro-inflammatory state.
TSPO Transcript and Protein Levels Are Induced in Mfp2
−/− Brain
We previously demonstrated that in MFP2-deficient brain, a robust and chronic neuroinflammation develops that is not accompanied by overt loss of neurons [17] . In order to analyze whether TSPO expression is increased in the CNS of Mfp2 −/− mice, we first examined the transcript levels. Quantitative RT-PCR showed increased Tspo mRNA in the brainstem of Mfp2 −/− mice as compared to control mice at an age of 12 weeks (Fig. 3a) . To ascertain that increased transcript levels are translated at the protein level, IHC was performed. Whereas TSPO immunoreactivity was hardly detectable in healthy control brain, TSPO was easily visualized throughout the whole Mfp2 −/− brain (shown for the brainstem, colliculus, and thalamus in Fig. 3b-g ).
Upregulated TSPO Colocalizes Predominantly with Reactive Microglia in Mfp2
−/− Brain An increased TSPO expression was generally considered to be dedicated to microglia, but recent literature suggests a potential contribution of reactive astrocytes [11, 29, 30] . In order to assess whether microglia, astrocytes, or both contribute to increased TSPO levels in Mfp2 −/− brain, IHC staining of TSPO protein with cell type-specific markers (Iba1 for microglia and GFAP for astrocytes) was performed. Nearly all Iba1 + microglia express TSPO in Mfp2 −/− brain (shown for the colliculus in Fig. 3i ) whereas only few GFAP + astrocytes show TSPO expression (marked by arrows, Fig. 3k ), indicating that increased TSPO levels are mainly attributed to reactive microglia in the Mfp2 −/− brain.
Increased [ 18 F]DPA-714 Uptake in Mfp2
−/−
Brain: In vitro Assessment of Brain TSPO Levels
In order to evaluate whether increased expression of TSPO in Mfp2 −/− brain could also be detected by using radiolabeled ligands for this protein, in vitro autoradiography employing [ 18 F]DPA-714, an established PET tracer for TSPO, was used in a first approach. The results showed significantly higher tracer binding in the Mfp2 −/− brain as compared to age-matched control brain (P G 0.0001; Fig. 4a,  b) . More specifically, high binding of [ 18 F]DPA-714 was observed in the colliculus, brainstem, corpus callosum, and hippocampus mirroring the immunofluorescent detection of TSPO (Fig. 4a) . We performed a blocking study using PK11195 (20 μM) as a blocking agent on brain slices of Ex vivo autoradiography has a 10-fold higher resolution than microPET and is therefore more sensitive to reveal increased tracer concentration in small brain areas. Analysis of the ex vivo autoradiography data showed significantly higher tracer binding in the Mfp2 −/− brain as compared to the agematched control brain both at 30 min (P = 0.0017) and 60 min (P G 0.0001) after [
18 F]DPA-714 injection ( Fig. 4d-g ).
MicroPET: In vivo Assessment of Brain TSPO Levels
Although the resolution of the microPET scanner (1.4 mm FWHM in the center) is low relative to the brain size of mice so that partial volume effects may obscure increase of tracer binding in small brain areas, we explored whether we would be able to detect increased −/− mice compared with that of controls (Fig. 5a, c) in line with the ex vivo autoradiography findings. When the TAC is expressed as standard uptake value (SUV), the initial brain uptake is clearly lower for Mfp2 −/− mice compared to that of control mice, whereas the clearance rate from the brain is slower for Mfp2 −/− mice (Fig. 5b, d ).
Discussion
Microglia can perform a multitude of tasks in the CNS depending on physiological-pathological conditions and adapt their gene expression profile accordingly. Although TSPO has been widely used as a reactive microglia-specific neuroinflammation imaging target [31] [32] [33] , it is unclear which microglial phenotypes are actually visualized [14] . By using in vitro and in vivo approaches, we demonstrate that TSPO is upregulated in pro-inflammatory microglia that, however, not necessarily reside in a destructive brain milieu.
In vitro, microglia can be manipulated and skewed into two extreme states, analogous to macrophages. The described M1-M2 subdivision nicely reflects the Janus-like behavior of microglia regarding their promotion of either versus control brain predominantly localize in Mfp2 −/− microglia. a qRT-PCR analysis shows induced Tspo transcript levels in the brainstem of Mfp2 −/− mice as compared to age-matched controls at 12 weeks of age. Data are presented as mean ± SEM (n = 3/group), **P G 0.01. IHC staining shows virtually no immunoreactivity for TSPO (green) in the b brainstem, c colliculus, and d thalamus of wild-type brain, but shows strong upregulation in the e brainstem, f colliculus, and g thalamus of Mfp2
−/− brain. IHC of h TSPO (green) and i Iba1 (red) to mark microglial cells. h In the healthy brain, TSPO levels are minimal so colocalization with Iba1 + microglia is not visible. i In the Mfp2 −/− mice, TSPO immunoreactivity colocalizes with nearly all Iba1 + microglia (orange). Merged picture and separate channels for Iba1 and TSPO are shown. IHC of j TSPO (green) and k GFAP (red) to mark astroglia. j Astrocytes of control mice minimally express GFAP and TSPO. k In the CNS of the Mfp2 −/− mice, only few GFAP + -reactive astrocytes colocalize with TSPO protein (orange). Merged picture and separate channels for GFAP and TSPO are shown. Representative pictures are shown from colliculus region.
tissue injury (M1) or repair (M2), but it is an oversimplified concept and only represents extreme states [34] . We show in this study that transcript levels of TSPO only increase in proinflammatory (M1) and not in anti-inflammatory (M2) microglial cells. Although this suggests that TSPO rather marks a harmful inflammatory brain environment and that TSPO is not induced in a purely neuroprotective or regenerative brain environment, this needs to be translated in vivo. There are several examples of neuroinflammatory conditions in which pro-inflammatory microglia prevail in which it was shown that TSPO is upregulated [24] [25] [26] . By i.c.v. injection of IL-4, we now elicited neuroinflammation that was primarily characterized by increased expression of anti-inflammatory markers. In this particular neuroinflammatory state, the expression of TSPO was unchanged, further proving that by tracking TSPO, only a subset of neuroinflammatory cells are revealed. Although microglia with either a pro-or antiinflammatory signature can occur in defined pathological conditions [22] , it is now accepted that microglia in vivo mostly adopt mixed pro-and anti-inflammatory phenotypes in neurological disorders [17, 34, 35] . It will be important to corroborate our findings in neurological disease states in which the microglial phenotypes have been well characterized. For example, in a mouse model of ALS, it was shown that M2 microglia are abundant in the early phase, whereas M1 microglia dominate at the end stage of the disease [36] .
This study also demonstrates that TSPO levels are clearly induced in vivo in a mouse model of peroxisomal MFP2 deficiency that develops robust neuroinflammation [17] . The results from the IHC staining were confirmed by in vitro and ex vivo autoradiography with [ −/− mice as compared to control at both 30 and 60 min after tracer injection (P G 0.01; two-tailed, unpaired Student's t test).
cannot be excluded. The difference between the nCi/cm 3 and SUV curves can be explained by a different brain-to-totalbody mass ratio for Mfp2 −/− versus control mice which influences the SUV. Mfp2 −/− mice are generally 25 % smaller than control mice [37] .
The cellular and molecular characteristics of the inflammatory response in Mfp2 −/− mice were previously extensively characterized [17] . It is noteworthy that the massive increase in myeloid cells was not due to infiltration of peripheral monocytes. Furthermore, the microenvironment in Mfp2 −/− brain deviates from the milieu in neurodegenerative disorders as there is neither neuronal loss nor oxidative stress during the entire lifespan of Mfp2 −/− mice despite the robust neuroinflammatory response [17] . Although the expanded microglia population expressed mixed pro-and anti-inflammatory markers, it should be noted that Mfp2 −/− microglia do not upregulate neurotoxic and oxidative stress markers such as Nos2, IL-6, and Icam1 [16, 17] . Thus, our data reveal that TSPO labels pro-inflammatory microglia that do not have a neuro-destructive character [38] .
Taken together, the in vitro data showing that TSPO expression is not increased in anti-inflammatory circumstances supports its use as a marker for proinflammatory microglia imaging. However, TSPO upregulation does not distinguish whether microglia develop a neuro-destructive signature or not. An additional caveat regarding TSPO is that a human TSPO polymorphism with a trimodal distribution in binding affinity (high-affinity, lowaffinity, and mixed affinity binders) was uncovered for several TSPO ligands [39] . This implicates that knowledge of binding status is needed to correctly quantify TSPO expression using these PET ligands in humans [39] . Also, the fact that the particular function of TSPO in mounting the inflammatory response remains obscure is a drawback for its use as a biomarker.
Therefore, it is highly desirable to identify new targets that allow specific visualization of neurotoxic microglia. P2X7, for which versatile radiotracers were already developed, might be a good marker besides other candidates [40, 41] . In addition, in view of the therapeutic potential to convert pro-inflammatory into anti-inflammatory microglia [22] , there is also a need to selectively detect the latter microglia by in vivo imaging in order to assess the therapeutic benefit. Given the ill-defined molecular phenotype of healing microglia [22] , this will be a more difficult task.
